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Abstract: Molecular xenomonitoring (MX), the detection of filarial DNA in mosquitoes using molecular methods (PCR), is a potentially useful surveillance strategy for lymphatic filariasis (LF) elimination
programs. Delay in filarial antigen (Ag) clearance post-treatment is a limitation of using human surveys to provide an early indicator of the impact of mass drug administration (MDA), and MX may be
more useful in this setting. We compared prevalence of infected mosquitoes pre- and post-MDA (2018
and 2019) in 35 primary sampling units (PSUs) in Samoa, and investigated associations between the
presence of PCR-positive mosquitoes and Ag-positive humans. We observed a statistically significant
decline in estimated mosquito infection prevalence post-MDA at the national level (from 0.9% to
0.3%, OR 0.4) but no change in human Ag prevalence during this time. Ag prevalence in 2019 was
higher in randomly selected PSUs where PCR-positive pools were detected (1.4% in ages 5–9; 4.8% in
ages ≥10), compared to those where PCR-positive pools were not detected (0.2% in ages 5–9; 3.2% in
ages ≥10). Our study provides promising evidence for MX as a complement to human surveys in
post-MDA surveillance.
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1. Introduction
Lymphatic filariasis (LF) is a globally significant parasitic disease which can result in
severe morbidity and disability, such as lymphedema, elephantiasis or scrotal hydroceles.
Elimination programs for vector-borne diseases such as LF, malaria and onchocerciasis
represent significant global health investments. Since 2000, the World Health Organization’s
(WHO) Global Programme to Eliminate LF has facilitated mass drug administration (MDA)
of anti-filarial drugs to >910 million people in 68 countries [1]. Despite huge successes over
>20 years, LF remains endemic in many countries. Most infections are asymptomatic but
may still contribute to transmission. Identifying residual infections is therefore critical for
programmatic decision-making such as stopping or resuming MDA.
The standard diagnostic test used in LF programmatic surveys detects circulating
filarial antigen (Ag), produced by adult worms [2]. Although Ag can be detected quickly
and inexpensively in the field using rapid diagnostic tests such as the Alere Filariasis Test
Strip [2], they cannot distinguish between current and recently cleared treated infections.
Some people remain Ag-positive for months or years after treatment but are not positive

Trop. Med. Infect. Dis. 2022, 7, 203. https://doi.org/10.3390/tropicalmed7080203

https://www.mdpi.com/journal/tropicalmed

Trop. Med. Infect. Dis. 2022, 7, 203

2 of 15

for microfilariae (Mf, immature parasites) and do not contribute to ongoing transmission.
As countries work towards elimination and LF Ag prevalence drops to very low levels,
highly sensitive surveillance methods will be required to detect changes in prevalence and
monitor progress. One such alternative indicator of transmission is the presence of Mf in
the blood, which confirms active infection. However, Mf may not be detected even if adult
worms are present, e.g., if the worms are too young, too old, or have not mated.
Molecular xenomonitoring (MX) involves testing mosquitoes for filarial DNA using
the polymerase chain reaction (PCR). Although PCR does not differentiate between a
mosquito that is infectious or recently infected, the mosquitoes’ short life span means
that the presence of PCR-positive pools indicates that an infectious person was recently
nearby [3]. MX may therefore potentially provide a more sensitive measure of where LF
transmission is occurring than Ag in humans, as well as an earlier signal of change in
transmission. MX has been used in research settings in American Samoa [4], Sri Lanka [5]
and India [6], although significant knowledge gaps still exist regarding survey design
and interpretation of results. Recent studies have highlighted the need for more efficient
mosquito collection methods, better understanding of the relationship between results
from MX and human surveys [7], and whether classifying mosquitoes into species groups
improves the usefulness of MX results (especially in countries where entomology expertise
is limited) [4,8].
LF is endemic in Samoa, transmitted by Aedes mosquitoes including the highly
efficient Aedes polynesiensis, with a flight range of ~150 m [9,10]. Samoa has conducted
LF elimination programs under GPELF since 1998 [11], with eight nationwide and two
subnational MDAs with DEC and albendazole conducted between 1999 and 2011. Population coverage was sub-optimal in the early campaigns but was over 65% in the five
most recent rounds of MDA [11]. Programmatic coverage for the 2018 triple-drug MDA
was 83.9% of the eligible population [12]. However, programmatic surveys in 2013 and
2017 [11] and research projects in 2018 [13] showed ongoing transmission. In 2018, Samoa
was the first country to distribute nationwide triple-drug MDA (ivermectin, albendazole and diethylcarbamazine) [12]. Evaluating the effectiveness of this intervention is
therefore of interest globally, but a key challenge is the ability to detect reductions in
human infection prevalence post-MDA. Considering that Ag could persist for months or
years after treatment [14], MX might provide a more sensitive surveillance strategy in
the post-MDA setting.
In this study, we aimed to evaluate the effectiveness of MX for LF surveillance by
comparing the results of spatially representative MX surveys with human Ag prevalence
surveys conducted in 2018 (baseline) and 2019 (follow-up) in Samoa. The main objectives were to: (i) estimate the prevalence of LF infection in mosquitoes at baseline and
follow-up surveys; (ii) assess the usefulness of MX as an indicator of human Ag prevalence, (iii) compare the usefulness of MX and human Ag for detecting changes in infection
prevalence for LF surveillance, and (iv) determine whether separating the mosquitoes
into different species prior to aggregating into pooled samples would alter the estimated
infection prevalence of the overall sample. Results were considered in a practical context
based on what can realistically be achieved on the ground and how findings can be used to
assist programmatic decision-making.
2. Materials and Methods
2.1. Study Region
Samoa is a tropical island nation in the South Pacific with approximately 201,316 residents
in 2018 [15], the majority of whom live on the islands of Upolu and Savai’i (Figure 1). Villages are predominantly rural, with urbanised areas around the capital of Apia and the
Savai’i ferry port of Salelologa. Average rainfall is 3000–6000 mm/year [16] and inland
areas remain largely forested. The predominant LF vector species is the day-biting Ae. polynesiensis, with evidence that night-biting Ae. samoanus (included in Ae. (Finlaya) subgenus)
is likely also able to transmit Wuchereria bancrofti [17].
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Figure 1. Map of Samoa showing approximate locations of the 35 primary sampling units (PSUs).
Villages included in each PSU are given in Supplementary Figure S1.1. Spatial data on country, island,
region, and village boundaries in Samoa were obtained from the Pacific Data Hub (pacificdata.org
accessed on 8 July 2020) and DIVA-GIS (diva-gis.org, accessed on 12 August 2019). Regions are Apia
Urban Area (AUA), North-West Upolu (NWU), Rest of Upolu (ROU) and Savai’i (SAV).

2.2. Selection of Primary Sampling Units (PSUs) and Households
Surveys were conducted in Upolu, Savai’i, and Manono islands across 35 PSUs (30
randomly selected and five purposively selected because of high Ag prevalence in previous
human surveys). To select the random PSUs for sampling, 30 villages were selected from a
line list of 338 villages in the 2016 national census; the first village was randomly selected,
and every 11th village from this starting point was included. For eight selected villages with
population of <600, the next village on the list was added to the PSU. Five additional villages
were purposively selected by the Samoa Ministry of Health due to high Ag prevalence in
previous surveys [13]. Therefore, our study included a total of 35 PSUs, each consisting of
one or two villages. Average PSU population size was 1355 (range 136 to 4289). The same
PSUs were sampled in both years. Human surveys in 2018 and 2019 and the mosquito
survey in 2019 included all 35 PSUs. For the 2018 mosquito survey, we were able to sample
28 of the 30 randomly selected PSUs before the start of the MDA, and the five purposively
selected PSUs were not included.
Within each PSU, 10 (2018 mosquito survey) or 15 households (2019 mosquito survey;
2018 and 2019 human surveys) were selected using a “virtual walk” method as described
previously [13]. If a selected location was not a household, or was uninhabited (destroyed,
abandoned, unoccupied), it was replaced by the closest house. If a PSU consisted of two
villages, the number of house locations per village was proportionate to each village’s
population. Spatial data on country, island, region and village boundaries in Samoa were
obtained from the Pacific Data Hub (pacificdata.org; accessed on 8 July 2020) and DIVAGIS (diva-gis.org; accessed on 9 August 2019). Geographic information systems software
ArcMap (v10.6, Environmental Systems Research Institute, Redlands, CA, USA) was used
to manage spatial data and produce maps.

1
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2.3. Data Collection
2.3.1. Mosquito Survey
Mosquito surveys were conducted on Upolu and Savai’i from 2 July to 25 August 2018
(within two months pre-MDA), and on Upolu, Savai’i and Manono Island from 20 May to
6 July 2019 (nine to ten months post-MDA). A survey timeline for human and mosquito
surveys is provided in Figure 2.

Figure 2. Timeline of 2018 and 2019 surveys (human and mosquitoes) relative to the rollout of the
triple-drug mass drug administration [18] in Samoa.

In 2018, the target sample size for mosquitoes was based on a positivity threshold of
an upper 1-sided confidence interval <0.25%, using results from Schmaedick et al. (2014) [7]
in American Samoa, which found infection prevalence in Ae. polynesiensis of >0.25% (0.28%,
95% CI: 0.20%, 0.39%). Using a design effect of two, the estimated target sample size
was 13,700 mosquitoes. Based on the work of Chambers et al. (2009) [19] in American
Samoa, the expected catch per 10 traps per 24 h was 180 mosquitoes. Thus, for 30 PSUs
with 10 trap sites/PSU, the expected catch was 10,800/48 h, the maximum possible time
per PSU to enable most PSUs to be surveyed before the start of the MDA. The number of
mosquitoes caught in 2018 was lower than expected and therefore, in 2019 the number of
households per PSU was increased from 10 to 15 for a total of 525 48 h household trapping
periods compared to 280 in 2018.
Traps were placed at each household for 48 h. We used BioGents Sentinel Mosquito
Traps (Models 1 and 2 with attractant lures), based on previous findings of their effectiveness when targeting Aedes mosquitoes in Samoa [20]. We used a BioGents synthetic lure
that mimics the human skin scent, and targets unfed host-seeking mosquitoes. Traps were
serviced twice daily in 2018 and once daily in 2019, to collect mosquito bags and replace
batteries. Mosquitoes at ambient temperatures can be damaged during transit as they
fly around inside bags, hampering species classification. To minimise this, trap-bags of
mosquitoes were transported in chilled containers. Mosquitoes were euthanized by placing
the trap-bag in a freezer, or in a resealable bag containing an acetone-soaked cotton-ball.
Male mosquitoes were discarded.
Female mosquitoes were sorted by species under a stereomicroscope (Make: Olympus,
Model: SZ61) using established taxonomic keys [21–23]. Four categories were used in 2018:
Ae. polynesiensis, Ae. (Finlaya) spp. (including Ae. samoanus), Culex spp., and all other Aedes
spp. Additional entomological capacity in 2019 enabled sorting into nine categories: Ae.
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polynesiensis, Ae. aegypti, Ae. albopictus, Ae. upolensis, Ae. (Finlaya) spp., Aedes spp. (other),
Cx quinquefasciatus and Culex spp. (other). Mosquitoes that could not be classified at a
species level were identified to genus level as Aedes spp. (other) or Culex spp. (other). All
classification at the species level was carried out by qualified entomologists or trained
technicians. To reduce workload, initial sorting by sex and genus (Aedes vs. Culex) was
undertaken by non-entomologists who had been trained and were competent in making
this initial distinction.
Each species/category of mosquito was placed into pools of 1–25 mosquitoes in 1.5 mL
Eppendorf tubes. In 2018, mosquitoes for each species and PSU were pooled separately,
but mosquitoes from different households were sometimes combined to minimise the
total number of pools per PSU and reduce laboratory costs. Increased catch numbers in
2019 enabled a more precise pooling strategy, where each pool contained a single species
from one household. Pooled mosquitoes in open tubes were oven-dried at 60 ◦ C for
three hours, and tubes placed in boxes with silica gel desiccant and shipped to Smith
College, USA. Samples underwent DNA extraction using the DNeasy Blood and Tissue Kit
(Qiagen, Hilden, Germany). Extractions were conducted using a modified version of the
manufacturer’s suggested protocol which has been previously described [7]. Following
extraction, all samples were tested for the presence of W. bancrofti using the real-time PCR
assay [24] using all recommended recipes and protocols.
2.3.2. Human Seroprevalence Survey
The baseline survey was conducted from 26 September to 9 November in 2018, within
two months after the start of MDA. Considering that Ag persists for at least months after
treatment, results were expected to be very similar to pre-MDA Ag prevalence. The followup survey was conducted from 28 March to 17 May 2019, seven to nine months post-MDA
and immediately prior to the 2019 MX survey (see Figure 2 for survey timeline). The survey
design has been previously described [13]. We tested blood samples for Ag using Alere
Filariasis Test Strips. For Ag-positive samples, blood slides were prepared and screened for
the presence of Mf using standard procedures [13].
2.4. Data Analysis
2.4.1. Mosquito Abundance
For each survey year, we calculated mosquito abundance as the number of female
mosquitoes collected from all traps over the two-day trapping period. Mosquitoes not
classified as either Culex or Aedes were excluded. We reported abundance by region
and species.
2.4.2. Prevalence of PCR-Positive Mosquitoes
Prevalence of mosquitoes infected with W. bancrofti was estimated from pool tested
results using the R package PoolTestR [25]. The function PoolPrevBayes was used with
default uninformative priors to fit Bayesian, mixed effect, multivariable logistic regression
models modified for pooled data with variable pool sizes. To determine whether there was
an association between mosquito abundance and PCR positivity in the randomly selected
PSUs, we used modified logistic regression models adjusting for mosquito genus and
clustering at the PSU level, stratified by year. To compare mosquito abundance between
the two years, the total number of vectors trapped at each PSU was divided by the number
of traps. The presence/absence results for PSUs for Ae. polynesiensis and “all species” were
mapped to examine the distribution.
Mosquito Infection Prevalence in Randomly vs. Purposively Selected PSUs in 2019
To compare prevalence between randomly and purposively selected PSUs in 2019, we
fitted a multivariable model with fixed/population effects for region, species and selection
method (random/purposive) and random/group effects for PSU. The OR and 95% credible
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intervals (CrI) for purposively vs. randomly selected villages was used to determine
differences and statistical significance.
To examine the usefulness of MX for detecting changes in infection rates from MDA,
we compared the estimated prevalence in 2018 and 2019. For models comparing prevalence
between years, we only included data from the 28 PSUs sampled in both years and collapsed
species categories to those used in 2018.
2.4.3. Human Antigen Prevalence
Human Ag prevalence for each year was estimated at national and regional levels,
using data from the 30 randomly selected PSUs. Sample size calculations were based on
numbers required to detect a critical threshold of 2% Ag prevalence in each age group,
with a 5% chance of type 1 error, 75% power (when true prevalence is 1%), a design effect
of 2.0, and correcting for the finite population. Statistical analyses were performed using
Stata (version 16, Stata Corp, College Station, TX, USA). Estimates were calculated using
the proportion command for each age category (5–9 and ≥10 years), adjusting for selection
probability at PSU and individual levels, and for clustering at PSU level. Results were
standardized by gender and (for those aged ≥10 years) by age group using 5-year categories
in the 2016 census. Finite population correction (FPC) was applied since sampling was
without replacement.
For human Ag, ORs for change in prevalence from 2018 to 2019 were estimated by
region and nationally for each age group (5–9 and ≥10 years) using melogit, adjusting for
selection probability at PSU and individual levels, and for clustering at PSU. Age, gender
and region were included as fixed effects.
2.4.4. Comparison of Antigen Prevalence in PSUs with or without PCR-Positive
Mosquito Pools
To assess whether the presence of PCR-positive mosquitoes was a useful indicator
of infections in humans, we compared Ag prevalence between PSUs with PCR-positive
mosquito pools and PSUs where no PCR-positive pools were detected. This analysis was
conducted using the randomly selected PSUs where both MX and human Ag surveys were
conducted (28 PSUs in 2018, and 30 PSUs in 2019).
2.4.5. Comparison of Human Ag and Mosquito Infection Prevalence between Baseline
(2018) and Follow-Up (2019)
To examine changes over time at the national or regional level, we fitted multivariable
models with fixed/population effects for vector species and, random/group effects for each
PSU at baseline (2018), and random/group effects for the temporal change in each PSU.
Region was not included as a covariate as approximate leave-one-out cross validation [26]
indicated including it did not improve the model. To examine changes over time by region,
we modified the model to include fixed/population effects for each region in 2018 and
fixed/population effects for the temporal change. From these models we calculated ORs
(which approximate prevalence ratios as prevalence was low) and 95% CrI to quantify
differences between years at national, regional and PSU levels. As a sensitivity analysis, we
fitted alternative models adjusting for genus rather than species, or without adjustment for
either. To compare each surveillance method in the baseline and follow-up surveys, we used
prevalence estimates by year in 28 PSUs that were surveyed in both years. We calculated
ORs (2019 vs. 2018) to determine significant changes in prevalence between years.
3. Results
3.1. Mosquito Abundance
In 2018, a total of 8506 female mosquitoes were trapped (Table 1), with a mean of
320 per PSU (range 147–781, median 278), equating to a mean of 30.4 mosquitoes per
trap over 280 traps. Culex were the predominant category (n = 4333, 48%), followed by
Aedes polynesiensis (n = 2498, 28%), other Aedes spp. (n = 1443, 16%) and Ae. (Finlaya) spp.
(n = 698, 8%). The predominant species in the Culex and Aedes (other) categories were Cx.
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quinquefasciatus and Ae. aegypti, respectively. Numbers of Ae. polynesiensis by PSU ranged
from 9 to 248 (mean 89, median 69).
Table 1. Number of female mosquitoes caught by species category and region, Samoa 2018. Regions
are Apia Urban Area (AUA), North-West Upolu (NWU), Rest of Upolu (ROU) and Savai’i (SAV).
Region

Ae. polynesiensis

Ae. (Finlaya) spp.

Aedes spp. (Other)

Culex spp. (All)

All Species

AUA
NWU
ROU
SAV

467
1140
313
578

242
60
178
218

179
803
296
165

848
1954
847
684

1736
3957
1634
1645

Total

2498

698

1443

4333

8972

In 2019 a total of 34,299 female mosquitoes were trapped (Table 2), with a mean of
980 per PSU (range 290–3719, median 855), equating to an average of 65.3 mosquitoes per
trap over 525 traps. Cx. quinquefasciatus was the predominant species (n = 17,807, 52%),
followed by Ae. polynesiensis (n = 10,540, 31%), Ae. aegypti. (n = 3396, 10%) and Ae. (Finlaya)
spp. (n = 1377, 4%). Numbers of Ae. polynesiensis varied by PSU with a range of 22 to 1046
(mean 301, median 173). Abundance for all species by PSU for both years is available in
Supplementary Tables S2.1 and S2.2.
Table 2. Number of female mosquitoes caught by species category and region, Samoa 2019. Regions
are Apia Urban Area (AUA), North-West Upolu (NWU), Rest of Upolu (ROU) and Savai’i (SAV).
Region

Ae. polynesiensis

Ae. aegypti

Ae. (Finlaya)
spp.

Aedes spp.
(Other)

Cx. quinquefasciatus

Culex spp.
(Other)

Other

All Species

AUA
NWU
ROU
SAV

1232
3443
2642
3223

623
1432
822
519

15
107
206
1049

54
283
508
291

2965
5823
7179
1840

0
0
1
23

2
9
3
5

4891
11,097
11,361
6950

Total

10,540

3396

1377

1136

17,807

24

19

34,299

3.2. Precence and Prevalence of PCR-Positive Mosquitoes
In 2018, 50% (14/28) of PSUs returned at least one PCR-positive pool of Ae. polynesiensis
and 82% (23/28) returned at least one PCR-positive pool of “any species”. Results were
similar in 2019, with 63% (22/35) of PSUs returning at least one PCR-positive pool of Ae.
polynesiensis and 80% (28/35) returning at least one PCR-positive pool of “any species”
(Figure 3).
In 2018, mosquitoes were sorted into 475 pools (mean 18 mosquitoes/pool, range
1–25); 18% (86/475) of pools were positive for W. bancrofti DNA by PCR. The highest
positivity rate of pools was 30% in Aedes spp. (other) (31/105 pools), followed by 24% for
Ae. polynesiensis (33/136 pools) (Supplementary Table S3.1). Nationally, estimated infection
prevalence in all species combined was 0.9% (95% credible interval [CrI] 0.2–2.3), with
the highest prevalence in Aedes spp. (other) (1.6%) followed by Ae. polynesiensis (1.2%).
Highest prevalence was found in the regions of Northwest Upolu (NWU) followed by
Rest of Upolu (ROU) (Figure 4, Supplementary Table S3.2). At the sub-regional level,
NWU (Musumusu and Faleapuna) and southeast Savai’i (Papa and Tafua) had the highest
prevalence (Supplementary Table S3.3).
In 2019, mosquitoes were sorted into 2638 pools (mean 13 mosquitoes/pool, range
1-25). The highest positivity rate of pools within the randomly selected PSUs was 9.2%
(56/612 pools) in Ae. polynesiensis followed by 6.5% for Ae. aegypti (70). Most pools consisted
of Cx. quinquefasciatus (39%) or Ae. polynesiensis (27%). Within all PSUs, 7% (172/2638) of
pools were PCR-positive. The highest positivity rate of pools was 14% in Ae. polynesiensis
(102/723), followed by 7% for Ae. aegypti (33/469). Estimated infection prevalence in
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all species combined was 0.3% (95% CrI 0.05–1.0%), with the highest prevalence in Ae.
polynesiensis (0.6%) (Figure 4). Highest prevalence was again observed in NWU followed
by Apia Urban Area (AUA) (Figure 4). At the PSU level, three purposively chosen PSUs in
NWU not sampled in 2018 Lauli’i (7.5%), Fasito’o Tai (7.1%) and Faleasiu (6.4%)—had the
highest prevalence (Supplementary Figure S3.1, Supplementary Table S3.4).

Figure 3. Presence of female mosquitoes (Ae. polynesiensis and “any species”) PCR-positive for W.
bancrofti by primary sampling unit (PSU), Samoa. Data from 2018 shown in the left semicircle, and
2019 in the right semicircle.

Figure 4. Estimated infection prevalence (%) by mosquito species, region and year (using data from
the 28 randomly selected primary sampling units (PSUs) surveyed in both 2018 and 2019), Samoa.
AUA = Apia Urban Area; NWU = North-West Upolu; ROU = Rest of Upolu; SAV = Savai’i. Values
provided in Supplementary Table S3.1.

Combining results of the 28 PSUs that were sampled in both years, estimated mosquito
infection prevalence for the country was lower in 2019 than 2018 for both the entire sample
(“all species”) (0.3% vs. 0.9%) and Ae. polynesiensis (0.5% vs. 1.2%). This decreasing trend

Trop. Med. Infect. Dis. 2022, 7, 203

9 of 15

was observed across all species categories nationally and in all regions, although not all
differences were statistically significant (Figure 4). There was no association between
PSU mosquito abundance and PCR positivity in 2018 (OR 0.84, 95% CrI: 0.53–1.32) or
2019 (OR 0.85, 95% CrI: 0.71–1.01). Mosquito abundance was therefore not adjusted for in
other analyses.
Mosquito Infection Prevalence in Randomly vs. Purposively Selected PSUs in 2019
In 2019, crude infection prevalence in all mosquito species in randomly selected PSUs
was 0.3% (95% CrI 0.05–1.05%), lower than the 1.1% (95% CrI 0.1–3.9%) in purposively
selected PSUs (Supplementary Table S3.1). This difference remained statistically significant
after adjusting for mosquito species, region, and clustering within PSUs (OR 0.24, 95% CrI
0.06–0.86). For both randomly and purposively selected PSUs, the highest prevalence was
observed in Ae. polynesiensis (0.6% and 1.8%, respectively), followed by Ae. aegypti (0.5%
and 1.5%, respectively).
3.3. Human Antigen Prevalence
In the 2018 baseline survey, we recruited 1542 participants aged 5–9 years and 1551
participants aged ≥10 years from 30 randomly selected PSUs [13]. In the 2019 follow-up
survey, we recruited 1811 participants aged 5–9 years and 1815 participants aged ≥10 years
from the same 30 PSUs. Participants numbers in 2018 and 2019 in each of the four regions
are given in Supplementary Tables S4.1 and S4.2. Figure 5 shows that in both 2018 and 2019,
the adjusted Ag prevalence at national and regional levels were higher for the ≥10 age
group. After stratification by region, ORs for the 5–9-year-old group could not be estimated
in two regions (AUA and ROU) because there were no Ag-positives in 2019.

Figure 5. Adjusted antigen prevalence from human survey in 2018 and 2019 for 30 randomly selected
primary sampling units (PSUs) in Samoa for (a) 5–9 year-olds and (b) ≥10 year-olds. Adjusted for
selection probability at PSU and individual levels, clustering at the PSU level, finite population
correction, and standardized for age and gender.
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3.4. Comparison of Antigen Prevalence in PSUs with or without PCR-Positive Mosquito Pools
In 2018, of the 28 random PSUs where both MX and human Ag surveys were conducted in both years, PCR-positive pools were found in 82% of PSUs (23/28). This decreased to 77% of PSUs in 2019 (23/30). Ag prevalence in PCR-positive PSUs was higher
than in PCR-negative PSUs for both age groups and years except for in 5–9-year-olds
in 2018 (Figure 6). The distribution of PCR-positive and Ag-positive PSUs is given in
Supplementary Figure S5.1.

Figure 6. Estimated Ag prevalence in primary sampling units (PSUs) with and without PCR-positive
mosquito pools in (a) 2018 and (b) 2019.

3.5. Comparison of Human Ag and Mosquito Infection Prevalence between Baseline (2018) and
Follow-Up (2019) Surveys
MX showed a significant reduction in mosquito infection prevalence from 2018 to 2019
nationally and in all regions for “all species” and Ae. polynesiensis (Figure 7). After adjusting
for mosquito species and clustering within PSUs, infection prevalence at the national level
was lower in 2019 than 2018 (OR 0.4, 95% CrI 0.2–0.6) and in three regions (NWU: OR 0.6
[95% CrI 0.4–0.9], ROU: OR 0.1 [95% CrI 0–0.2], SAV: OR 0.3 [95% CrI 0.1–0.8]). Estimated
prevalence declined in AUA, but the difference was not statistically significant (OR 0.6, 95%
CrI 0.2–1.5). Given the low prevalence, these ORs closely approximate prevalence ratios.
For example, infection prevalence in mosquitoes in ROU was ~90% (i.e., 1–0.1) lower in
2019 than in 2018.

Figure 7. Change in prevalence from 2018 to 2019 in Samoa, expressed as an odds ratio (OR), for
mosquito infection prevalence (MX for all species and Ae. polynesiensis), and human antigen prevalence (in those aged ≥10 years, and 5–9 years). Given the low prevalence, the ORs are approximately
equal to prevalence ratios. ORs < 1 indicate decrease in infection prevalence in 2019 compared to
2018, ORs > 1 indicate an increase, and OR of 1 indicate no change. OR could not be calculated for
5–9-year-olds in AUA and ROU because no antigen-positive cases were detected in these groups in
2019. AUA = Apia Urban Area; NWU = North-West Upolu; ROU = Rest of Upolu; SAV = Savai’i.
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There was no significant change in Ag prevalence between the two surveys in participants aged ≥10 years or 5–9 years at the national level. Variable patterns were observed
at the region level, with a significant increase in Ag prevalence between 2018 and 2019 in
5–9-year-olds in NWU (OR 2.2, 95% CI 1.0–4.9) and in ≥10-year-olds in SAV (OR 1.9, 95%
CI 1.5–2.5) but a significant decrease in ≥10-year-olds in AUA (OR 0.3, CI 0.1–0.7).
Even though our study was designed to detect differences at national and regional
levels, we also observed statistically significant reductions in mosquito infection prevalence
between 2018 and 2019 in 10 PSUs, and prevalence did not increase in any PSUs (Supplementary Table S6.1). Adjustment for genus or species had little effect on the point estimate
or confidence intervals for the difference in prevalence between 2018 and 2019 at national,
regional or PSU levels (Supplementary Figures S7.1 and S7.2)
4. Discussion
This study demonstrated the value of MX as an effective tool for LF surveillance, with
a potentially higher sensitivity than human Ag prevalence for detecting early changes
in infection levels following triple-drug MDA. After one round of triple-drug MDA in
Samoa, MX detected a decline in prevalence of infected mosquitoes, while there was no
significant change in Ag prevalence between the two human community surveys conducted
six months apart. We compared MX results for the main vector Ae. polynesiensis and all
species combined and found that temporal trends in mosquito infection prevalence were
similar between regions.
Higher numbers of female mosquitoes were caught in 2019 than 2018, partly due to
drier conditions in 2018 and partly due to the additional seven PSUs and larger number
of households per PSU (15 instead of 10) surveyed in 2019. In 2019, survey teams were
also more proactive with trap placements to increase catches (e.g., if few mosquitoes were
trapped in the first 24 h, the trap was moved to another part of the house for the next 24 h).
The increased catch numbers in 2019 resulted in more pools, leading to higher workload
and laboratory costs but provided more precise infection prevalence estimates. Although
the number of PCR-negative PSUs is potentially related to mosquito abundance (i.e., the
more mosquitoes tested, the higher the probability that one of them will test positive),
analysis confirmed that prevalence of infection in mosquitoes was not correlated with the
average catch numbers per trap. It is, however, possible that the number of PCR-positive
PSUs in 2018 could be an underestimate due to the low catch numbers caused by a lower
survey effort (ten traps per PSU than 15) and adverse weather conditions during and prior
to trapping.
Several factors could potentially influence the estimated mosquito infection prevalence.
These include prevalence of infectious humans nearby, mosquito biting rate, and the chance
that infected and uninfected mosquitoes are trapped. We believe that a decrease in the
prevalence of infectious humans nearby is the most likely explanation for a reduction
in mosquito infection prevalence in Samoa. Although mosquito behavioural changes or
seasonal changes are theoretical possibilities that could increase or decrease transmission
intensity, there is no evidence that these factors are operating over the time scale studied. If
MX is to be used as a routine surveillance strategy, future studies should be designed to
specifically answer this question and optimise interpretation of MX results.
Mosquitoes categorised as “Aedes other” in 2018, most likely to be Ae. aegypti, had a
higher pool PCR positivity rate and infection prevalence than Ae. polynesiensis in 2018, but
the observation was reversed in 2019. Aedes spp. had a dramatically higher pool positivity
rate and infection prevalence than that of Culex spp. The large numbers of Culex spp. pools
therefore diluted the overall infection prevalence of “all species” combined. Where prior
knowledge of endemic mosquito species distribution and infection prevalence are available,
this can be used to inform the pooling strategy for MX as to whether certain mosquito
categories can be excluded from PCR analysis.
Comparison between mosquito categories showed higher infection prevalence in Aedes
spp. than Culex spp. Nevertheless, analyses using “all species” or only Ae. polynesiensis
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had similar spatial and temporal trends, though the larger sample sizes with “all species”
resulted in tighter confidence intervals, illustrating one advantage of using all mosquito
samples available. Sorting mosquitoes by species requires substantial expertise. MX surveys
could be greatly simplified if sorting were restricted to the genus level. Promisingly, despite
the differences in infection prevalence between Culex and Aedes mosquitoes and between Ae.
polynesiensis and other Aedes mosquitoes, adjustment for genus or species had little effect
on the point estimate or confidence interval for the difference in prevalence between 2018
and 2019 at national, regional or PSU levels. This finding suggests that, for the purposes of
detecting temporal trends, sorting by genus or species in our study made little difference to
the results or their interpretation. Whether this observation can be generalised to future
surveys in Samoa or elsewhere requires further investigation. If the relative abundance
of species captured were substantially different between two time points or two survey
locations to be compared, failing to sort by species may bias comparisons.
The pool PCR positivity rate and mosquito infection prevalence were three times
greater in the purposively selected than the randomly selected PSUs. This was expected
since the purposively selected PSUs had historically high LF prevalence, which highlights
the importance of local knowledge for identifying areas of high transmission. Mosquito
infection prevalence in randomly selected PSUs was lower in 2019 than 2018 nationally
and in each region (Figures 4 and 7), but this difference was not statistically significant
for AUA.
When comparing MX and Ag for post-MDA surveillance, we found a statistically
significant decrease in infection prevalence in mosquitoes at the country level for “all
species” and Ae. polynesiensis, but no significant change overall in Ag prevalence in
5–9-year-olds or in those aged ≥10 years. This could be due to a slower change in Ag
compared to mosquito infection prevalence. These results demonstrate each surveillance
method’s sensitivity to changing prevalence, and when used together may provide a
more complete picture. MX may provide a more accurate picture of the transmission
potential from humans to mosquitoes at specific time points, whereas Ag, due to its more
gradual decline, provides a smoother trend over time. Although the significant reduction
in mosquito infection prevalence suggests an encouraging impact on LF transmission
by the MDA, transmission from humans to mosquitoes was not completely interrupted,
suggesting the possibility of ongoing transmission. Pedersen et al. (2009) [3] used modelling
and empirical data to estimate thresholds of 0.085% L3 larvae prevalence in mosquitoes or
0.65% for any stage of filarial worm infection in mosquitoes; but these predicted thresholds
have not been validated with field studies [3].
Our results should be considered in light of the study’s limitations. In 2018, the
sample size of households required to trap sufficient mosquitoes was calculated using the
best available evidence, but dry weather conditions led to lower-than-expected catches.
Operational challenges in 2018 also led to simplified pooling by reducing the number of
mosquito categories. In 2019, protocol changes and wetter conditions led to increased
catches. Mosquitoes were pooled between households in 2018, so prevalence estimates
could not be adjusted for household-level clustering. Comparisons of relative magnitude
and changes in human and mosquito infection prevalence over time depend on close
overlap and frequent contact between the two populations. In most cases, the traps were
located at or near the households selected for the human survey, except where this was not
possible (no suitable location, residents not home for second survey etc.), in which case
they were placed as close as possible (for example at a neighbouring property). We do not
believe this is a major limitation as even if placed at the same households, the traps would
be sampling mosquitoes that may have acquired infection at other nearby households.
In conclusion, our study suggests that in the immediate post-MDA period, MX might
be more sensitive than Ag for detecting changes in transmission. However, if the goal is
to detect the presence of residual transmission, Ag and MX surveys may provide complementary information. In MX, using both the primary mosquito species and other species
increased the sample size and improved the ability to detect transmission and changes in
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prevalence. In our study, adjusting for species made very little difference to estimates of
infection prevalence, suggesting that the labour-intensive process of sorting mosquitoes
into species categories did not influence the overall results or their interpretation. In countries where the expertise required to trap and identify mosquitoes is limited, omitting the
requirement to classify them into species groups could make MX more feasible. Further
research is required to determine whether our findings are generalisable to future surveys
in Samoa and to other settings.
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